Postoperative	0	13	O
progression	14	25	O
of	26	28	O
pulmonary	29	38	B-Organ
metastasis	39	49	O
in	50	52	O
osteosarcoma	53	65	B-Pathological_formation
.	65	66	O

Early	68	73	O
relapse	74	81	O
with	82	86	O
distant	87	94	O
metastasis	95	105	O
often	106	111	O
is	112	114	O
observed	115	123	O
in	124	126	O
patients	127	135	B-Organism
with	136	140	O
cancer	141	147	B-Pathological_formation
after	148	153	O
resection	154	163	O
of	164	166	O
the	167	170	O
primary	171	178	O
tumor	179	184	B-Pathological_formation
.	184	185	O

It	186	188	O
is	189	191	O
considered	192	202	O
that	203	207	O
resection	208	217	O
of	218	220	O
the	221	224	O
primary	225	232	O
tumor	233	238	B-Pathological_formation
induces	239	246	O
activation	247	257	O
of	258	260	O
systemic	261	269	O
angiogenesis	270	282	O
and	283	286	O
enhances	287	295	O
progression	296	307	O
of	308	310	O
remote	311	317	O
metastasis	318	328	O
.	328	329	O

The	330	333	O
authors	334	341	O
show	342	346	O
that	347	351	O
resection	352	361	O
of	362	364	O
the	365	368	O
primary	369	376	O
osteosarcoma	377	389	B-Pathological_formation
tumor	390	395	I-Pathological_formation
enhances	396	404	O
progression	405	416	O
of	417	419	O
pulmonary	420	429	B-Organ
metastasis	430	440	O
in	441	443	O
animal	444	450	O
osteosarcoma	451	463	B-Pathological_formation
models	464	470	O
.	470	471	O

Matrigel	472	480	O
plug	481	485	O
neovascularization	486	504	O
assay	505	510	O
revealed	511	519	O
that	520	524	O
systemic	525	533	O
angiogenic	534	544	O
activity	545	553	O
was	554	557	O
elevated	558	566	O
after	567	572	O
primary	573	580	O
tumor	581	586	B-Pathological_formation
removal	587	594	O
(	595	596	O
tumor	596	601	B-Pathological_formation
intact	602	608	O
group	609	614	O
,	614	615	O
1	616	617	O
.	617	618	O
61	618	620	O
+	621	622	O
/	622	623	O
-	623	624	O
0	625	626	O
.	626	627	O
21	627	629	O
g	630	631	O
/	631	632	O
dL	632	634	O
;	634	635	O
tumor	636	641	B-Pathological_formation
removed	642	649	O
group	650	655	O
,	655	656	O
4	657	658	O
.	658	659	O
92	659	661	O
+	662	663	O
/	663	664	O
-	664	665	O
0	666	667	O
.	667	668	O
35	668	670	O
g	671	672	O
/	672	673	O
dL	673	675	O
)	675	676	O
.	676	677	O

In	678	680	O
addition	681	689	O
,	689	690	O
serum	691	696	B-Organism_substance
concentration	697	710	O
of	711	713	O
the	714	717	O
angiogenesis	718	730	O
inhibitor	731	740	O
,	740	741	O
endostatin	742	752	B-Gene_or_gene_product
,	752	753	O
decreased	754	763	O
significantly	764	777	O
after	778	783	O
primary	784	791	O
tumor	792	797	B-Pathological_formation
removal	798	805	O
.	805	806	O

Treatment	807	816	O
with	817	821	O
the	822	825	O
antiangiogenic	826	840	O
reagent	841	848	O
TNP	849	852	B-Drug_or_compound
-	852	853	I-Drug_or_compound
470	853	856	I-Drug_or_compound
suppressed	857	867	O
postoperative	868	881	O
progression	882	893	O
of	894	896	O
pulmonary	897	906	B-Organ
metastasis	907	917	O
.	917	918	O

These	919	924	O
results	925	932	O
indicate	933	941	O
the	942	945	O
possibility	946	957	O
that	958	962	O
activation	963	973	O
of	974	976	O
angiogenic	977	987	O
activity	988	996	O
after	997	1002	O
resection	1003	1012	O
of	1013	1015	O
osteosarcoma	1016	1028	B-Pathological_formation
tumors	1029	1035	I-Pathological_formation
enhances	1036	1044	O
progression	1045	1056	O
of	1057	1059	O
pulmonary	1060	1069	B-Organ
metastasis	1070	1080	O
.	1080	1081	O

The	1082	1085	O
current	1086	1093	O
data	1094	1098	O
also	1099	1103	O
suggest	1104	1111	O
that	1112	1116	O
administration	1117	1131	O
of	1132	1134	O
antiangiogenic	1135	1149	O
reagents	1150	1158	O
can	1159	1162	O
prevent	1163	1170	O
progression	1171	1182	O
of	1183	1185	O
pulmonary	1186	1195	B-Organ
metastasis	1196	1206	O
in	1207	1209	O
osteosarcoma	1210	1222	B-Pathological_formation
postoperatively	1223	1238	O
.	1238	1239	O

